A
A
    Global websites
    Local websites
    language header world map

    Innovation

    The Science of Collaboration

    We bring our antibody engineering expertise to pioneering researchers with the intent to advance immunology breakthroughs into differentiated medicines for patients.

    Through collaboration, we have a common purpose and can accelerate discovery processes to bring solutions to patients who need them.

    We know that together we are better.

    Immunology Innovation Program (IIP)

    The Immunology Innovation Program (IIP) is a core business strategy of argenx connecting the specialized insight into disease and target biology of our external scientific and academic collaborators with our unparalleled experience as antibody engineers.

    Co-creation has led to a deep pipeline of highly differentiated product candidates.

    Through the IIP, we hope to together transcend breakthrough research and publications to our ultimate and unifying mission of creating new potential treatment options for patients.

    An Innovation Ecosystem

    "Stepping into these strategic, academic, industry collaborations. This is a wonderful ecosystem that we are creating, by bringing that expertise together.”

    Prof. Bart Lambrecht

    Bringing expertise together

    Academic Collaborators

    Bern University

    Columbia University

    Institut de Duve

    Leiden University

    Ludwig Cancer Research

    National Jewish Health

    Université Catholique de

    Louvain

    Turin University

    University Of

    Pennsylvania

    NYU School of Medicine

    UT Southwestern

    Flemish Institute for

    Biotechnology

    Utrecht University

    Antibody Engineering

    Innovation and co-creation are at the core of our strategy. We integrate our unique antibody engineering capabilities with the deep disease and target biology expertise of our collaborators. By innovating at the discovery level, we have built a broad pipeline of differentiated potential immunology solutions to offer patients.

    We innovate at both the variable region or V region (where antigens and foreign proteins are recognized) and the constant region or Fc region (where antibodies modulate other cells in the immune system):

     Antibody

    V region

    innovation-1 FC region

    Technology Role

    Suite of Technologies

    Unlock novel and complex targets

    SIMPLE Antibody™ Platform

    SIMPLE Antibody™ is argenx's proprietary platform designed to source V regions from the immune system of "outbred" llamas.

    Modulate immune response

    Three Fc engineering technologies (NHANCE®, ABDEG™ and POTELLIGENT®) are intended to expand the therapeutic index of argenx antibodies.

    Unique suite of technologies enables development of differentiated product candidates against novel targets

    Partnering opportunities

    Deep relationships power the core of our innovation ecosystem, it is a system of co-creation.

    The Immunology Innovation Program is based on mutual respect for the expertise that each partner brings. Our research collaborators bring unique knowledge of disease biology or a disease pathway. argenx can offer antibody engineering capabilities and a path to turn an immunology breakthrough into a clinical development candidate.

    We together with our partners have the potential to create differentiated medicines for patients.

    For more information on partnering opportunities, please contact BD@argenx.com

    lock-image

    argenx respects your privacy
    Personal information is never kept longer than necessary. Personal data is not provided to third parties without permission or used for marketing purposes.

    2024 © argenx
    Disclaimer
    Privacy policy
    2024 © argenx
    Disclaimer
    Privacy policy